These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22938056)

  • 1. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
    Keating GM; Lyseng-Williamson KA; Frampton JE
    BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib: in medullary thyroid cancer.
    Frampton JE
    Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vandetanib for the treatment of medullary thyroid cancer.
    Chau NG; Haddad RI
    Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ; Seib CD; Gosnell J
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH; Robinson BG; Learoyd DL
    Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
    Ton GN; Banaszynski ME; Kolesar JM
    Am J Health Syst Pharm; 2013 May; 70(10):849-55. PubMed ID: 23640345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective use of vandetanib in the treatment of thyroid cancer.
    Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
    Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
    Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
    Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
    Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.
    Pilco Teran M; Merino Ribas A; Martin Alemany N; Barros Freiria X; Rubio Casadevall J; Pérez Bueno F; García Méndez I; Castillo Devia M; Noboa Paez C; Torguet Escuder P; Calabia Martínez J
    Invest New Drugs; 2021 Feb; 39(1):237-239. PubMed ID: 32648118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
    Thornton K; Kim G; Maher VE; Chattopadhyay S; Tang S; Moon YJ; Song P; Marathe A; Balakrishnan S; Zhu H; Garnett C; Liu Q; Booth B; Gehrke B; Dorsam R; Verbois L; Ghosh D; Wilson W; Duan J; Sarker H; Miksinski SP; Skarupa L; Ibrahim A; Justice R; Murgo A; Pazdur R
    Clin Cancer Res; 2012 Jul; 18(14):3722-30. PubMed ID: 22665903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vandetanib (Caprelsa) for medullary thyroid cancer.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):3-4. PubMed ID: 22233588
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.
    Hadoux J; Schlumberger M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):335-347. PubMed ID: 28911729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib for the treatment of medullary thyroid carcinoma.
    Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
    Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.